<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00868985</url>
  </required_header>
  <id_info>
    <org_study_id>PEG-01/2007(ELE)</org_study_id>
    <nct_id>NCT00868985</nct_id>
  </id_info>
  <brief_title>Effects of Oral PEG 3350 on Electrolyte Balance</brief_title>
  <official_title>Effects of Oral PEG 3350 on the Electrolyte Balance in Patient Volunteers With Chronic Constipation:Pharmacokinetic Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norgine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Norgine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to evaluate the influence of three different doses of PEG 3350 with or without
      electrolytes on the electrolyte balance in patient volunteers with confirmed chronic
      constipation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Electrolyte profile in blood, urine and faeces, serum osmolality and effect on the renin/aldosterone ratio</measure>
    <time_frame>Ten days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of PEG 3350 in plasma, urine and faeces</measure>
    <time_frame>Ten days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Chronic Constipation</condition>
  <arm_group>
    <arm_group_label>PEG 3350 plus electrolytes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were dosed with PEG 3350 with electrolytes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG 3350 without electrolytes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were dosed with PEG 3350 without electrolytes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG 3350 plus electrolytes</intervention_name>
    <description>Each patient was treated with PEG 3350 with electrolytes for 10 days at a dose of either one, two or three sachets per day.</description>
    <arm_group_label>PEG 3350 plus electrolytes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG 3350 without electrolytes</intervention_name>
    <description>Each patient was treated with PEG 3350 for 10 days at a dose of either one, two or three sachets per day.</description>
    <arm_group_label>PEG 3350 without electrolytes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subjects written informed consent must be obtained prior to inclusion.

          2. Male and female patients between 18 and 70 years of age with confirmed chronic
             constipation after the run-in period; this is defined as patients who have recorded in
             their diaries less than 3 bowel motions/week plus one of the following symptoms:

             Straining during at least 25% of defecations Lumpy or hard stools with at least 25% of
             defecations Sense of incomplete evacuation with at least 25% of defecation Sensation
             of ano-rectal blockage with at least 25% of defecation Manula manoeuvres of facilitate
             at least 25% of defecation

          3. Willing and able to follow the entire procedure and to comply with the study
             instructions.

          4. For the subgroup of patient volunteers taking ACE-inhibitors (36 subjects): A history
             of hypertension, with blood pressure controlled to acceptable levels by a stable
             regimen of ACE-inhibitors.

        Exclusion Criteria:

          1. Participation in a clinical research study involving investigational drugs or dosage
             forms within the previous 3 months.

          2. Subjects who have previously been enrolled in this study.

          3. Subjects who are currently or have a history of abuse of alcohol, non-medical drugs,
             medicinal drugs or other substance abuse eg solvents.

          4. Major surgery in within the last 12 months.

          5. Malignant tumors within the last 5 years.

          6. Uncontrolled blood pressure or terminal cardiac, liver and/or kidney diseases.

          7. Clinical relevant acute gastrointestinal tract disease, including evidence of
             intestinal perforation or obstruction, paralytic ileus, toxic megacolon, severe
             inflammatory conditions.

          8. Acute urinary tract conditions, including cystitis.

          9. Patients with diagnosis or evidence of the following diseases: Hypothyroidism,
             diabetes mellitus, porphyria, pituitary gland insufficiency, pheochromocytoma,
             glucagonoma, neurological diseases (eg Hirschprung disease, neurofibromatosis, Chagas
             disease, stroke, autonomous neuropathy, intestinal pseudoobstruction, Multiple
             sclerosis, medullar injury, Parkinson disease, Shy-Drager syndrome), collagenosis,
             vasculitis, myopathy (e.g. sclerodermatitis, amyloidosis, dermatomyositis),
             intoxication with heavy metals (e.g. Pb, As, Hg)

         10. Concomitant medication:

               1. Use of any oral purgatives/laxatives and prokinetics within the last 14 days
                  prior to dosing.

               2. Use of any opioids, anti-cholinergics, tricyclic anti-depressants, MAOIs, Fe
                  preparations, within the 4 weeks prior to dosing.

               3. Use of any Ca-antagonists, Beta-blockers or diuretics within the last 4 weeks
                  prior to dosing.

               4. other medication which in the opinion of the Investigator could interfere with
                  the principal function of the GI tract.

         11. Subject unable to provide written consent.

         12. Failure to satisfy the Investigator of fitness to participate for any other reason,
             including suspected non-compliance.

         13. Women of childbearing potential, who are not using and not willing to use medically
             reliable methods of contraception for the entire study duration, unless they are
             surgically sterilised/hysterectomised or any other criteria considered sufficiently
             reliable by the Investigator in individual cases.

         14. Patients with electrolytes disturbances or clinical signs of dehydration.

         15. Positive test at screening for HIV or hepatitis.

         16. Any clinically significant abnormal test results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-JÃ¼rgen Gruss, MD</last_name>
    <role>Study Director</role>
    <affiliation>Norgine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rodica Cinca, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IFE Human Pharmacology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IFE Human Pharmacology</name>
      <address>
        <city>Timisoara</city>
        <zip>Ro-300244</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2009</study_first_submitted>
  <study_first_submitted_qc>March 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2009</study_first_posted>
  <last_update_submitted>March 24, 2009</last_update_submitted>
  <last_update_submitted_qc>March 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Vice President Clinical Development</name_title>
    <organization>Norgine Ltd</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyethylene glycol 3350</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

